Direct oral and fiber-derived butyrate supplementation as an anti-obesity treatment via different targets
Clinical Nutrition · 2024-03 · 43 (3) · 869-880
DOI: 10.1016/j.clnu.2024.02.009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Nutrition, 2024-03. Verfasst von Zuzanna Majka und 10 weiteren Autor:innen. Beteiligte Einrichtung: Jagiellonian Centre of Experimental Therapeutics (JCET), Jagiellonian University, 14 Bobrzynskiego Str., Krakow 30-348, Poland; Faculty of Chemistry,…. Hauptthemen laut MEDLINE: Obesity, beta-Glucans. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Narodowe Centrum Nauki.
Abstract (Originalsprache)
BACKGROUND & AIMS: Butyric (one of the short-chain fatty acids), a major byproduct of the fermentation of non-digestible carbohydrates (e.g. fiber), is supposed to have anti-obesity and anti-inflammatory properties. However, butyrate's potential and mechanism in preventing obesity and the efficient form of administration remain to be clarified. METHODS: Hence, we studied the effect of oral supplementation with 5% (w/w) sodium butyrate and 4% (w/w) β-glucan (fiber) on young male mice (C57BL/6J) with high-fat diet-induced obesity (HFD: 60 kcal% of fat + 1% of cholesterol). Six weeks old mice were fed diets based on HFD or control (AIN-93G) diet with/without supplements for 4 weeks. The unique, interdisciplinary approach combining several Raman-based techniques (including Raman microscopy and fiber optic Raman spectroscopy) and next-generation sequencing was used to ex vivo analyze various depots of the adipose tissue (white, brown, perivascular) and gut microbiome, respectively. RESULTS: The findings demonstrate that sodium butyrate more effectively prevent the pathological increase in body weight caused by elevated saturated fatty acids influx linked to a HFD in comparison to β-glucan, thereby entirely inhibiting diet-induced obesity. Moreover, butyrate significantly affects the white adipose tissue (WAT) reducing the epididymal WAT mass in comparison to HFD without supplements, and decreasing lipid saturation in the epididymal WAT and perivascular adipose tissue of the thoracic aorta. Contrarily, β-glucan significantly changes the composition and diversity of the gut microbiome, reversing the HFD effect, but shows no effect on the epididymal WAT mass and therefore the weight gain inhibition is not as effective as with sodium butyrate. CONCLUSIONS: Here, oral supplementation with sodium butyrate and β-glucan (fiber) has been proven to have an anti-obesity effect through two different targets. Administration-dependent effects that butyrate imposes on the adipose tissue (oral administration) and microbiome (fiber-derived) make it a promising candidate for the personalized treatment of obesity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jagiellonian Centre of Experimental Therapeutics (JCET), Jagiellonian University, 14 Bobrzynskiego Str., Krakow 30-348, Poland; Faculty of Chemistry, Jagiellonian University, 2 Gronostajowa Str., Krakow 30-387, Poland.
- Department of Clinical Biochemistry, Jagiellonian University Medical College, 8 Skawinska Str., Krakow 31-066, Poland.
- Department of Molecular Medical Microbiology, Faculty of Medicine, Jagiellonian University Medical College, 18 Czysta Str., Krakow 31-121, Poland.
- Jagiellonian Centre of Experimental Therapeutics (JCET), Jagiellonian University, 14 Bobrzynskiego Str., Krakow 30-348, Poland.
- Faculty of Chemistry, Jagiellonian University, 2 Gronostajowa Str., Krakow 30-387, Poland.
- Department of Molecular Medical Microbiology, Faculty of Medicine, Jagiellonian University Medical College, 18 Czysta Str., Krakow 31-121, Poland. Electronic address: tomasz.gosiewski@uj.edu.pl.
Förderung
- Narodowe Centrum Nauki
Zitieren
APA
Majka, Z., Zapala, B., Krawczyk, A., Czamara, K., Mazurkiewicz, J., Stanek, E., Czyzynska-Cichon, I., Kepczynski, M., Salamon, D., Gosiewski, T., & Kaczor, A. (2024). Direct oral and fiber-derived butyrate supplementation as an anti-obesity treatment via different targets. Clinical Nutrition, 43(3), 869-880. https://doi.org/10.1016/j.clnu.2024.02.009
Vancouver
Majka Z, Zapala B, Krawczyk A, Czamara K, Mazurkiewicz J, Stanek E, et al. Direct oral and fiber-derived butyrate supplementation as an anti-obesity treatment via different targets. Clinical Nutrition. 2024;43(3):869-880. doi:10.1016/j.clnu.2024.02.009
BibTeX
@article{Majka2024,
author = {Majka, Zuzanna and Zapala, Barbara and Krawczyk, Agnieszka and Czamara, Krzysztof and Mazurkiewicz, Joanna and Stanek, Ewa and Czyzynska-Cichon, Izabela and Kepczynski, Mariusz and Salamon, Dominika and Gosiewski, Tomasz and Kaczor, Agnieszka},
title = {Direct oral and fiber-derived butyrate supplementation as an anti-obesity treatment via different targets},
journal = {Clinical Nutrition},
year = {2024},
volume = {43},
number = {3},
pages = {869--880},
doi = {10.1016/j.clnu.2024.02.009}
}
EUVIMED